quilibrative nucleoside transporters (ENTs), members of the solute carrier transporter family SLC29, are integral membrane proteins that play central roles in nucleoside-related physiology, pathophysiology, and pharmacology 1, 2 . There are four human ENT isoforms (hENT1−hENT4), each of which exhibits diverse tissue and subcellular localizations, substrate specificities and pharmacological properties. Of these isoforms, hENT1 has been the central focus of many studies, owing to its crucial role in adenosine and nucleoside analog drug transport [1] [2] [3] [4] . Adenosine is a key signaling molecule affecting cardiovascular function and neuromodulation in human physiological and pathological states, including epilepsy, alcohol preference, pain, ischemia and inflammation [5] [6] [7] . hENT1, an energy-independent uniporter with a preferred specificity for adenosine, is responsible for controlling adenosine signaling by regulating its extracellular and intracellular levels and is thus the target of adenosine reuptake inhibitors (AdoRIs) 1, 2, 8, 9 . A chemically diverse group of nucleoside analogs and non-nucleosides, AdoRIs increase extracellular concentration of adenosine by blocking hENT1 function and are used clinically as vasodilators and antithrombotic drugs for the treatment of cardiopathy, renal disorders and hypertension 1, 2, 10, 11 . There has been recent interest in improving the pharmacological properties of AdoRIs, along with the identification of novel human ENT1 inhibitors [12] [13] [14] [15] . hENTs are responsible for the transport of over 30 Food and Drug Administration-or European Medicines Agency-approved nucleoside-derived anticancer, antiviral and antihypertensive drugs 2 . Importance of hENT1 for the efficacies of these drugs is highlighted by numerous studies that report a high level of correlation between hENT1 expression and survival outcome of patients with pancreatic cancer receiving the nucleoside-derived anticancer agent gemcitabine [16] [17] [18] [19] [20] [21] [22] [23] . Despite the importance of hENT1, our understanding of hENT1 and its inhibition by AdoRIs is limited, partly because no experimental structure is available for any SLC29 family transporter 1 . Further, the SLC29 family is evolutionarily distinct from the structurally characterized SLC28 concentrative nucleoside transporter family [24] [25] [26] . Additionally, the ENT family does not have any prokaryotic orthologs, and AdoRI action is highly isoform and species specific 1,2 , thus requiring structural study of hENT1 in complex with AdoRIs to understand the mechanism of inhibition shown on the transporter. Here, we present two structures of hENT1: one in complex with the adenosine analog AdoRI NBMPR and the other in complex with the non-nucleoside AdoRI dilazep, a clinically used vasodilator. To our knowledge, these are the first experimental structures to describe the SLC29 family protein fold. Together with functional studies, the structural data presented here provide mechanistic insight into hENT1-mediated adenosine transport and its inhibition. Notably, we found that NBMPR blocks the transporter in a unique manner, which provides mechanistic insight into the inner workings of hENT1 and a starting point for the rational design of therapeutics with enhanced pharmacologic properties.
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Crystallization of human ENT1 in complex with dilazep or NBMPR
To achieve the level of stability required for structural study, point mutations and disordered-loop truncations were screened for enhanced biochemical behavior (Methods). After exhaustive screening, we identified three point mutations (L168F, P175A and N288K) to enhance transporter detergent solution behavior. Additionally, a disordered-loop truncation (∆Pro243−Gln274) previously reported to have no effect on hENT1 functional activity 27 was found to enhance detergent solution behavior of the transporter. Combining this loop truncation and three point mutations resulted in a functionally competent construct (hENT1 cryst , Supplementary Note 1) that mediates nucleoside transport to a level consistent with that found in a previous report 28 ( Supplementary  Fig. 1 ), while retaining binding capacity to the hENT1-specific inhibitor NBMPR (Fig. 1a) . The transporter behavior was further enhanced substantially by incorporating the non-nucleoside AdoRI dilazep during protein expression and purification. The dilazepbound hENT1 cryst was crystallized in lipidic cubic phase, yielding diffraction of X-rays to 2.3-Å resolution. Experimental phases to 3.5 Å were obtained by single-isomorphous replacement anomalous scattering (SIRAS) from platinum-soaked crystals (Table 1 and Supplementary Fig. 2 ). The final dilazep-bound hENT1 structure is of excellent quality with a R free factor of 24%. We also crystallized Structures of human ENT1 in complex with adenosine reuptake inhibitors Nicholas J. Wright and Seok-Yong Lee *
The human equilibrative nucleoside transporter 1 (hENT1), a member of the SLC29 family, plays crucial roles in adenosine signaling, cellular uptake of nucleoside for DNA and RNA synthesis, and nucleoside-derived anticancer and antiviral drug transport in humans. Because of its central role in adenosine signaling, it is the target of adenosine reuptake inhibitors (AdoRI), several of which are used clinically. Despite its importance in human physiology and pharmacology, the molecular basis of hENT1-mediated adenosine transport and its inhibition by AdoRIs are limited, owing to the absence of structural information on hENT1. Here, we present crystal structures of hENT1 in complex with two chemically distinct AdoRIs: dilazep and S-(4-nitrobenzyl)-6-thioinosine (NBMPR). Combined with mutagenesis study, our structural analyses elucidate two distinct inhibitory mechanisms exhibited on hENT1 and provide insight into adenosine recognition and transport. Our studies provide a platform for improved pharmacological intervention of adenosine and nucleoside analog drug transport by hENT1.
hENT1 cryst in complex with the nucleoside-derived AdoRI NBMPR, which exhibits merohedral twinning. Phases were obtained from the dilazep-bound hENT1 structure by molecular replacement, and refinement was carried out against the X-ray data to 2.9-Å resolution (Methods, Fig. 1b and Supplementary Fig. 3 ).
Transporter architecture
Dilazep-bound hENT1 cryst was crystallized as a single monomer in the asymmetric unit. Consistent with previous accessibility studies of hENT1 (ref. 29 ), hENT1 cryst is composed of 11 transmembrane helices (TMs), with the N terminus on the cytosolic side and the C terminus on the extracellular side (Fig. 1c,d ). The structural architecture of the transporter exhibits a pseudo-symmetric 6 + 5 topology in which the first six TMs forms one bundle, which we termed the N domain, and the final five TMs forms another bundle, which we termed the C domain (Fig. 1c,d and Supplementary  Fig. 4a ). It was previously speculated that the fold of ENT bears similarity to that of major facilitator superfamily (MFS) transporters, which exhibit a 6 + 6 topology and pseudo-symmetry between the first six TMs in the N domain and the second six TMs in the C domain 1, 2 . Structural superposition of hENT1 cryst to human Glut3 (ref. 30 ), a representative outward-facing MFS X-ray structure, shows that despite the low sequence identity (~17% sequence identity) and structural similarity (Cα r.m.s. deviation of 5.0 Å), the fold of hENT1 matches the first 11 TMs (TM1−TM11) out of 12 TMs in MFS ( Supplementary Fig. 4b ). Several structural features observed in hENT1 cryst are distinct from features consistent within MFS. First, because TM12 is absent in hENT1, TM9 in hENT1 is arranged to fit into the space occupied by both TM9 and TM12 in MFS, and thus, the location of TM9 in hENT1 is substantially different from that of TM9 in canonical MFS transporters ( Supplementary Fig. 4b ). Second, because of the asymmetry in the composition between the N and the C domains in hENT1, the structural symmetry in the two domains is relatively low, with a Cα r.m.s.d. of 4.0 Å compared with 3.0 Å in the canonical MFS transporter LacY or 3.3 Å in the MFS transporter hGlut3 (refs. 30, 31 ). The AdoRIs NBMPR and dilazep occupy the central cavity of the transporter, accessible to the extracellular side of the membrane, suggesting that both structures represent outward-facing conformations, consistent with the predictions from previous functional studies [32] [33] [34] [35] (Fig. 2a) . In both inhibitor-bound structures, the narrowest constriction point at the extracellular side occurs between Met33 of TM1 and Pro308 of TM7. Following the nomenclatures of MFS and SLC transporters, we tentatively named this region the 'extracellular thin gate' . The surface representations suggest that the thin gate prevents NBMPR from releasing into the extracellular side freely in the NBMPR-bound hENT1 structure, thus representing an outward-facing occluded conformation. On the contrary, a substantial part of dilazep is cradled around the thin gate, preventing complete occlusion of the thin gate (Fig. 2a,b) . At the cytosolic-facing side of hENT1 cryst , TM4, TM5, TM10 and TM11 feature extensive hydrophobic contacts, fully occluding access from the cytosolic side. Additional polar and charged interactions appear to stabilize this cytosolic gate of hENT-1 cryst (Fig. 2b) . We propose that this extensive network of hydrophobic, polar and charged interactions form the intracellular thick gate. Of these polar and charged interactions, Arg111 and Glu428 are exclusively conserved across mammalian ENTs and highly conserved across the entire ENT family, suggesting a functional role for these residues (Fig. 2b) . Furthermore, this interaction network observed between the two symmetry-related halves of hENT1 cryst at this site is distinct from the highly conserved A motif of MFS 36 , which is located at a structurally conserved position in human Glut3, suggesting a difference in transport mechanisms between the SLC29 family and MFS ( Supplementary Fig. 4c ).
Dilazep-binding site
A strong and unambiguous electron density peak for dilazep was observed early in model refinement against the high-resolution native data ( Fig. 3a and Supplementary Fig. 2 ). Dilazep, comprised of two trimethoxybenzenoic acid groups linked to a diazepane ring in the middle, adopts a crescent conformation. Each of the trimethoxyphenyl rings occupies a distinct site: one site deep within the central cavity and the other proximal to the extracellular side. Mapping previous mutagenesis studies indicated that amino acid residues important for nucleoside recognition are located in the central cavity [37] [38] [39] [40] [41] ( Supplementary Fig. 5a ). We therefore termed the site within the central cavity as the 'orthosteric site' and the site near the extracellular side as the 'opportunistic site 1' . In the orthosteric site, the trimethoxybenzoic acid group interacts with Trp29 from TM1 and Gln158 from TM4, both of which are in the N domain. The central diazepane ring is cradled by a hydrophobic contact with Met33 from TM1, a previously reported determinant of the isoform specificity exhibited by dilazep and dipyridamole 42, 43 . In the opportunistic site 1, the other trimethoxyphenyl ring forms π−π stacking interactions with Phe307 (TM7) and Phe334 (TM8) and a hydrogen bond with Asn338 from TM8, all of which are in the C domain. Consistent with our structural observation, Trp29, Phe334 and Asn338 have been previously shown to affect hENT1 transport sensitivity to dilazep when mutated 37, 44 ( Supplementary Fig. 5a ).
NBMPR-binding site
NBMPR is an adenosine analog inhibitor (Fig. 3b) ; therefore, the structure of hENT1 in complex with NBMPR can provide insight on the mechanisms of adenosine recognition by hENT1 as well as hENT1 inhibition. Deep within the central cavity of the transporter, we observed a prominent F o − F c omit electron density peak, of which the shape and size is consistent with NBMPR ( Fig. 3b and Supplementary Fig. 3 ). The central cavity, analogous to the orthosteric site in the dilazep−hENT1 structure, is occupied by the adenosine-like thioinosine moiety of NBMPR. The 2ʹ-OH and 3ʹ-OH of the ribose moiety of NBMPR interact with the side chains of conserved Arg345 and Asp341, respectively, both of which have been previously reported to be critical for nucleoside transport activity in the ENT family member Leishmania donovani LdNT2 (ref. 41 ). The conserved Gln158 coordinates to the N-1 and N-3 amino groups of the thioinosine moeity, suggesting that this residue might be important for nucleobase recognition. Furthermore, the hydrophobic residues, including Leu26, Met89, Leu92 and Leu442 lined by TM1, 2 and 11, also surround the purine moiety of NBMPR. Specifically, Leu26 and Leu442 sandwich the purine ring, supporting the previous finding in which the mutation of L442I converts nucleoside preference to uridine over adenosine in hENT1 (ref. 37 ). Met89 and Leu92 were also implicated in both purine and NBMPR binding 38, 39 ( Supplementary Fig. 5a ). We posit that adenosine recognition by hENT1 will be similar to the thioinosine binding by hENT1 in our structure. Therefore, hENT1 utilizes two conserved charged residues for ribose recognition, whereas nucleobase recognition is mediated by polar coordination of the conserved Gln158 and hydrophobic contacts within the central cavity.
Notably, the side of the central cavity proximal to the thioinosine moiety of NBMPR is connected to a deep hydrophobic pocket protruding into the transporter N domain, which is lined by TM1, TM3 and TM4. In the NBMPR−hENT1 complex structure, the p-nitrobenzyl ring occupies this hydrophobic cavity (Fig. 3b) . We refer to this cavity as the 'opportunistic site 2' . Directly abutting the p-nitrobenzyl ring of NBMPR within this cavity is Gly154, and the residue at the equivalent position in hENT2 and hENT3 is serine. Mutation to serine at this position in hENT1 was shown to result in a ~2,500-fold decrease in NBMPR inhibitory potency, and thus, Gly154 has been suggested to be a key determinant of the isoform specificity displayed by NBMPR 40 . Substituting glycine for serine at this position in the NBMPR− hENT1 structural model leads to narrowing of the hydrophobic cavity, which would hinder the binding of the p-nitrobenzyl ring of NBMPR (Supplementary Fig. 5b) , providing an explanation for the mutational effect of Gly154.
Shared and distinct binding sites of dilazep and NBMPR
Structural comparison of the NBMPR-and dilazep-bound hENT1 structures reveal shared and distinct amino acid residues for binding these two inhibitors. In the shared orthosteric site, Gln158 appears to be important for binding the purine ring of NBMPR and the trimethoxyphenyl ring in dilazep (Fig. 4a) . Because there were no previous mutagenesis studies on Gln158, we mutated Gln158 to either asparagine or serine and found that both mutations result in the abrogation of 3 H-NBMPR binding capacity (Fig. 4b) binding. To test this structural observation, we chose to mutate Phe307 in the opportunistic site 1, as this residue has not been previously studied. Whereas NBMPR binding was assayed by direct binding of 3 H-NBMPR, dilazep binding was assayed by displacement of bound 3 H-NBMPR. To validate our assay, we first mutated Met33 in the opportunistic site 1 to isoleucine and observed an ~3-fold increase in apparent K d for dilazep; there was no noticeable change in K d for NBMPR, consistent with previous mutagenesis studies concerning this specific hENT1 mutation 42, 45 . We then mutated Phe307 to alanine in hENT1 and found a resulting ~90-fold increase in apparent K d for dilazep, whereas the conservative mutation F307Y resulted in an ~four-fold decrease in apparent K d for dilazep. However, neither F307A nor F307Y had a noticeable effect on NBMPR binding in hENT1 (Fig. 4c,d ). Our functional studies confirmed the structural observation that the opportunistic site 1 contributes substantially to the binding energetics of dilazep but not NBMPR, whereas mutation at the shared orthosteric site disrupts NBMPR binding (because of disrupted NBMPR binding in the orthosteric site mutants, dilazep binding was not determined for Q158N and Q158S).
inhibitory mechanisms of dilazep and NBMPR
The structures presented here capture hENT1 in two inhibitorbound states, which provides insight into their inhibition mechanisms of hENT1. On the basis of the two-domain architecture, we reason that hENT1 will likely utilize global rocker-switch-like reorientation of N and C domains for the alternating-access mechanism, for its adenosine and nucleoside analog drug transport. These two inhibitor-bound states feature the transporter in outward-facing conformations in which the intracellular thick gate defines the outward-facing state of the transporter. In order for the transporter to transition into the inward-facing state, the extracellular thin gate is completed first upon substrate binding, then by the extracellular thick gate formation by N-and C-domain reorientation 46 ( Fig. 5) . In both inhibitor-bound hENT1 structures, dilazep and NBMPR share the orthosteric site within the central cavity of the transporter but explore distinct opportunistic sites for inhibition of the conformational transitions of the transporter. The opportunistic site 1 for the drug dilazep is located at the region including the extracellular thin gate and is occupied by the central diazepane ring and one of the two trimethoxyphenyl rings of the drug. Therefore, dilazep sterically prevents complete extracellular thin gate formation, which is required for the extracellular thick gate formation followed by the transition into the inward-facing state (Fig. 5) . This steric blocking of extracellular gate formation has commonly been employed by competitive inhibitors in MFS and sodium-coupled neurotransmitter transporters [47] [48] [49] [50] . In the NBMPR-bound hENT1 structure, because the opportunistic site 1 is not occupied, the extracellular thick gate formation is not sterically hindered. Notably, the p-nitrobenzyl ring of NBMPR protrudes deep into a hydrophobic cavity present within the N domain of hENT1 (the opportunistic site 2), and the adenosine-like thioinosine group occupies the orthosteric site of the transporter. Based on the previous studies highlighting the large conformational changes substrate-lining TMs undergo during the transport cycle 26 ,46,51 , we speculate that TM1, TM3 and TM4 that surround the opportunistic site 2 are important for conformational transition, and the occupancy of this site by the p-nitrobenzyl ring of NBMPR prevents the conformational rearrangement of the N domain required for transport (Fig. 5) .
To the best of our knowledge, all competitive inhibitor−bound transporter structures feature steric hindrance of gate closure 47, 49, 50, 52 ; a competitive inhibitor blocking the transporter using an extended moiety for allosteric control of the conformational transition is unprecedented.
Discussion
Our structural and mutagenesis studies reveal the structural basis of solute recognition and inhibition exhibited on a clinically relevant human SLC29 transporter. Our structures uncover the molecular architecture and design principles of the SLC29 family of nucleoside transporters for the first time. Prior to this work, the SLC29 family fold was hypothesized to adopt the highly conserved MFS . However, we found that the SLC29 family shows interesting differences from MFS, which follows a strict 12 TM topology. It is tempting to speculate that the differences observed between the SLC29 and MFS folds could result in mechanistic differences in solute transport. Second, in combination with a wealth of previous mutagenesis studies, our structures provide insight into the molecular features of nucleoside recognition and nucleoside preference exhibited by this human adenosine transporter. Third, our structural and mutagenesis studies help us understand how the non-nucleoside vasodilator dilazep can bind and inhibit hENT1, which offers an opportunity for the rational design of improved therapeutics modulating nucleoside transport. Last, our structural analyses together with previous and current mutagenesis studies suggest that NBMPR inhibits the transporter in a unique manner, which not only provides a glimpse of the inner workings of this transporter but also shows a previously unappreciated way to inhibit transporters of therapeutic target.
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Methods
Construct screening and optimization. The codon-optimized wild-type hENT1 was synthesized in the pCEH vector with a C-terminal GFP-His 10 tag for initial screening of transporter detergent solution stability with fluorescence sizeexclusion chromatography (FSEC) 53 . For additional screening, scale-up expression, purification and crystallization, the codon-optimized wild-type hENT1 cDNA was transferred to the pEG BacMam vector featuring a PreScission Protease cleavable FLAG-His 10 tagged C-terminal eGFP fusion 54 . The wild-type fusion transporter exhibits monodisperse gel filtration behavior in n-dodecyl-β-d-maltoside (DDM) detergent buffer; however, the transporter loses stability upon eGFP removal and subsequent purification. To achieve a level of transporter stability amenable to biophysical studies, we used consensus mutagenesis to improve the detergent solution behavior of purified hENT1. A panel of putative stabilizing mutations and disordered-loop truncations were screened for enhanced transporter detergent solution behavior. The final hENT1 construct used for crystallization (denoted as hENT1 cryst ) contains the point mutations L168F, P175A, N288K and TM6−7 loop truncation ∆243−274 (ref. 27 ), all of which were determined to enhance transporter behavior in DDM detergent.
Screening, expression and purification. The hENT1 cryst -GFP-FLAG-His 10 was overexpressed in HEK293S GnTI -cells by means of viral transduction 54 . 10 mM sodium butyrate and 10 μM dilazep were added to the virally induced cells 24 h post infection, and cells were harvested 72 h post infection. Total cell lysates containing dilazep-bound fusion recombinant transporter were solubilized in 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.5 mM TCEP and 40 mM n-dodecyl-β-d-maltoside (DDM) detergent for 1 h, then centrifuged at 16,000 r.p.m. for 25 min. Detergent-solubilized clarified lysate was incubated with FLAG M2 affinity resin for 1 h, and then resin was washed with 5CV high-salt buffer (20 mM Tris-HCl, pH 8.0, 500 mM NaCl, 1.0 mM DDM detergent, 0.5 mM TCEP, 10 μM dilazep), then with 5CV low-salt buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5 mM TCEP, 1.0 mM DDM detergent, 10 μM dilazep) and eluted with low-salt buffer supplemented with 0.2 mg/ml FLAG peptide (DYKDDDDK). Purified hENT1 cryst fusion was then concentrated to 0.75 mg/ml and treated with 1:10 PreScission Protease and 1:10 EndoH for 2 h, to simultaneously cleave the GFP-FLAG-His 10 tag and remove N-linked glycan. The deglycosylated free transporter was then further purified with size-exclusion chromatography (Superdex 200) in 20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5 mM DDM, 0.5 mM TCEP and 10 μM dilazep. For crystallization with NBMPR, protein expression and purification was consistent with the dilazep conditions, except expression was performed apo and NBMPR was incorporated at all stages of the preparation (10 μM during extraction and anti-FLAG purification, 1.0 μM during gel filtration). For proteoliposome reconstitution, protein was prepared apo, and 5.0 mM n-decyl-β-d-maltoside (DM) detergent was used in the final gel filtration step.
Crystallization. Inhibitor-bound hENT1 cryst was crystallized with the lipidic cubic phase method 55 . Purified inhibitor-bound protein was concentrated to 40 mg ml −1 before mixing with monoolein (Sigma) in a 40:60 weight/weight ratio. Crystallization was facilitated at room temperature in 96-well glass sandwich plates (MiTeGen) with 150 nl mesophase and 1.0 μl crystallization solution. The crystallization condition yielding the best diffracting crystals of the dilazep-bound hENT1 cryst consisted of 35-50% PEG 400, 0.1 M glycine, pH 9.0, and 0.5 M NaCl. Plate-like crystals appeared 12 h after setting up trays and reached a full size of 50 × 20 μm in 3-5 d. Wells were opened with a tungsten-carbide glass cutter (MiTeGen), and crystals were harvested with 75 μm MiTeGen micromounts and directly cooled in LN 2 . Dilazep−transporter crystals were used for the heavy-atom soaks for phasing, and soaks were carried out as described previously 56 . For all heavy-atom screens, soaks were carried out for 24 h prior to well re-opening and harvesting. For the NBMPR-bound hENT1 cryst structure, the crystal was obtained from 30% PEG 500 MME, 0.1 M magnesium chloride hexahydrate and 0.1 M Tris-HCl, pH 8.0. The crystal grew to full size after 7 d.
Structure determination. All data were collected on the NE-CAT remote access 24ID-C and 24ID-E beamlines at the Advanced Photon Source at a wavelength of 0.979 Å. The native data for the dilazep structure were processed with Mosflm, and the derivative data were processed with the NE-CAT RAPD pipeline 57 . A 90° wedge of a single hENT1 cryst dilazep crystal yielded a complete dataset, with X-rays diffracting beyond 2.1 Å in the best direction and a space group of P3 2 21. Owing to mild diffraction anisotropy, anisotropic truncation was performed with the STARANISO server. Of the initial heavy-atom derivatives screened, K 2 PtCl 4 soaks yielded crystals that were highly isomorphous to the native crystal and diffracted X-rays beyond 3.0-Å resolution. Full 360° datasets were collected on three separate isomorphous K 2 PtCl 4 -soaked crystals, and these datasets were combined to increase anomalous multiplicity. Phasing was performed using highresolution native data and merged derivative data with SIRAS. Platinum sites were determined with the SHELXC/D/E software suite 58 followed by phasing and extreme density modification to 5.0 Å with AutoSol in the Phenix software suite 59 , yielding a figure of merit (FOM) of 0.50. An initial partial model was built by placing 11 idealized alpha helices into the asymmetric unit of this experimental map, with unambiguous helix connectivity apparent for TMs 2-6. An experimental SIRAS map phase extended with extreme density modification to 3.5 Å (FOM of 0.33) was then utilized to confirm helix direction and to perform manual adjustments of the initial model. Combined phases were then determined from this initial model and anomalous dispersion from the merged platinum data (MR-SAD) to 3.5 Å and extended to 2.9 Å with density modification. The transporter was registered, and side chains were built for roughly 80% of the molecule using the resulting MR-SAD map. This working model was then transferred to the highest-resolution native data with molecular replacement, and iterative cycles of building and refinement in Phenix were performed. The final model is of good quality with a Phenix reported R work /R free = 0.20/0.24 and excellent Ramachandran statistics (98.7% favored, 1.3% allowed, no outliers), containing hENT1 residues 7-452 (hENT1 residues 1-6, 49-73, 241-280, 453-456 missing).
For the NBMPR-bound hENT1 cryst structure, a 110° wedge of a single crystal yielded a complete dataset and was processed with XDS 60 , with X-rays diffracting beyond 3.0 Å. Owing to moderate diffraction anisotropy, anisotropic truncation was performed with the STARANISO server. Intensity statistics indicated merohedral twinning with the apparent space group P622 and the actual space group P6 1 with the twin operator of h, -h-k, -l. The protein portion of the final dilazep-bound transporter structure was used as a search model for molecular replacement, resulting in the placement of two transporter molecules per asymmetric unit. Refinements were carried out against the anisotropically corrected X-ray data to a 2.9 Å, using an intensity-based twin refinement in Phenix 59 and Refmac5 (ref. 61 ). Free R flags were written in the highest possible point group of the lattice and subsequently expanded to the final space group of P6 1 to prevent cross-contamination between the working and free set during the twinned refinements. Multiple rounds of model building and refinement resulted in a Phenix reported R work /R free = 0.21/0.25. The final model exhibits good protein geometry (95.9% Ramachandran favored, 4.1% allowed, no outliers) and a Clashscore of 3.4.
Inhibitor binding assays. Scintillation proximity assays (SPAs) were performed using an anti-FLAG M2-purified hENT1-GFP-FLAG-His 10 fusion transporter and Cu-PVT beads in 20 mM Tris-HCl, 150 mM NaCl, 1.0 mM DDM and 0.5 mg/ml BSA in a total volume of 0.5 ml. For saturation binding of 3 H-NBMPR (5.5 Ci/mmol, Moravek Inc.) to wild-type and hENT1 cryst fusion constructs (Fig. 1a) , radiochemical was successively titrated onto 10 nM transporter immobilized to 4.0 mg/ml Cu-PVT beads, with scintillation counting after each addition. For saturation binding of 3 H-NBMPR to hENT1 cryst and mutants in the hENT1 cryst background (Fig. 4b) , radiochemical was successively titrated onto 6.25 nM transporter immobilized to 3.0 mg/ml Cu-PVT beads. K d was determined in GraphPad Prism, using a non-linear regression equation accounting for ligand depletion. For cold competition assays, unlabeled dilazep was titrated onto SPA mixture containing 85 nM fusion transporter, 100 nM 3 H-NBMPR and 3.0 mg/ml Cu-PVT beads. Apparent dilazep displacement K d values were determined from fitting the data in GraphPad Prism to a non-linear regression equation to describe competitive binding accounting for ligand depletion.
Transport assays. Nucleoside transport assays were performed in a counterflow manner, using purified hENT1 reconstituted into proteoliposomes. Protein purified in 5 mM DM was reconstituted using 10 mg ml −1 of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE) and 1-palmitoyl-2-oleoylsn-glycero-3-phospho-(1´-rac-glycerol) (POPG) in a 3:1 ratio in the presence of transport buffer (20 mM HEPES pH 7.4, 150 mM NaCl) as described previously 62 with the following adjustment: DM detergent was removed with 4 × 10 h treatment with 100 mg ml −1 BioBeads (BioRad). Reconstituted proteoliposomes were loaded with 1.0 mM cold uridine via five cycles of LiN 2 freeze−thaw, then extrusion through the Avanti Mini-Extruder loaded with a 1.0 μM filter. Extraliposomal cold nucleoside was removed from the loaded vesicles with illustra MicroSpin G-50 columns (GE Healthcare), and the transport reaction was immediately initiated by a 1:50 dilution of the proteoliposomes (v/v) into 500 μl transport buffer containing 0.2 μM 3 H-uridine (17 Ci/mmol, Moravek). Reactions were terminated after 90 s by rapid filtration of the assay mixture over a 1.0 μM GF/B glass microfiber filter (Whatman), then rapid washing with 4 × 2.0 ml transport buffer (performed on a 96-well Brandel harvester). Filters were then added to 5.0 ml liquid scintillation counting fluid and analyzed via scintillation counting after 12 h.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article. 
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